Skip to main content
Erschienen in: Current Hepatology Reports 4/2010

01.11.2010

Antiviral Therapy: Analysis of Long-term Efficacy and Safety

verfasst von: Helen S. Te

Erschienen in: Current Hepatology Reports | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Despite the adoption of universal vaccination in many countries, chronic hepatitis B virus (HBV) infection continues to be a global problem. Morbidity and mortality from this infection, although possibly declining, remains significant. Fortunately, our treatment armamentarium has expanded exponentially in the past decade. Newer antiviral agents are not only effective against HBV infection, but they also confer a lower risk for virologic resistance than the first-generation oral nucleoside, lamivudine. In this article, the long-term efficacy and safety of available antiviral therapy in the treatment of chronic hepatitis B are reviewed, and differences in drug potencies, side-effect profiles, and risks of development of virologic resistance are discussed to provide guidance for optimal choices for long-term antiviral therapy.
Literatur
1.
2.
Zurück zum Zitat Wong DK, Cheung AM, O'Rourke K, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312–323.PubMed Wong DK, Cheung AM, O'Rourke K, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312–323.PubMed
3.
Zurück zum Zitat Brunetto MR, Giarin M, Saracco G, et al.: Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993, 105:845–850.PubMed Brunetto MR, Giarin M, Saracco G, et al.: Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993, 105:845–850.PubMed
4.
Zurück zum Zitat Fattovich G, Farci P, Rugge M, et al.: A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992, 15:584–589.CrossRefPubMed Fattovich G, Farci P, Rugge M, et al.: A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992, 15:584–589.CrossRefPubMed
5.
Zurück zum Zitat Lampertico P, Del Ninno E, Manzin A, et al.: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997, 26:1621–1625.CrossRefPubMed Lampertico P, Del Ninno E, Manzin A, et al.: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997, 26:1621–1625.CrossRefPubMed
6.
Zurück zum Zitat Lampertico P, Del Ninno E, Vigano M, et al.: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756–763.CrossRefPubMed Lampertico P, Del Ninno E, Vigano M, et al.: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756–763.CrossRefPubMed
7.
Zurück zum Zitat Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2695.CrossRefPubMed Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2695.CrossRefPubMed
8.
Zurück zum Zitat Korenman J, Baker B, Waggoner J, et al.: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991, 114:629–634.PubMed Korenman J, Baker B, Waggoner J, et al.: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991, 114:629–634.PubMed
9.
Zurück zum Zitat Lau DT, Everhart J, Kleiner DE, et al.: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113:1660–1667.CrossRefPubMed Lau DT, Everhart J, Kleiner DE, et al.: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113:1660–1667.CrossRefPubMed
10.
Zurück zum Zitat Yuen MF, Hui CK, Cheng CC, et al.: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139–145.CrossRefPubMed Yuen MF, Hui CK, Cheng CC, et al.: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139–145.CrossRefPubMed
11.
Zurück zum Zitat Piratvisuth T, Lau GK, Marcellin P, et al.: Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (Pegasys) for HBeAg-positive chronic hepatitis B (CHB). J Hepatol 2006, 44:S23.CrossRef Piratvisuth T, Lau GK, Marcellin P, et al.: Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (Pegasys) for HBeAg-positive chronic hepatitis B (CHB). J Hepatol 2006, 44:S23.CrossRef
12.
Zurück zum Zitat Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.CrossRefPubMed Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.CrossRefPubMed
13.
Zurück zum Zitat Chan HL, Leung NW, Hui AY, et al.: A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240–250.PubMed Chan HL, Leung NW, Hui AY, et al.: A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240–250.PubMed
14.
Zurück zum Zitat Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123–129.CrossRefPubMed Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123–129.CrossRefPubMed
15.
Zurück zum Zitat • Buster EH, Hansen BE, Lau GK, et al.: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002–2009. This paper discusses the positive predictors of response to pegylated interferon to determine the optimal group of patients who may benefit from the drug. CrossRefPubMed • Buster EH, Hansen BE, Lau GK, et al.: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002–2009. This paper discusses the positive predictors of response to pegylated interferon to determine the optimal group of patients who may benefit from the drug. CrossRefPubMed
16.
Zurück zum Zitat Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256–1263.CrossRefPubMed Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256–1263.CrossRefPubMed
17.
Zurück zum Zitat Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562–568.CrossRefPubMed Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562–568.CrossRefPubMed
18.
Zurück zum Zitat Schiff ER, Dienstag JL, Karayalcin S, et al.: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003, 38:818–826.CrossRefPubMed Schiff ER, Dienstag JL, Karayalcin S, et al.: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003, 38:818–826.CrossRefPubMed
19.
Zurück zum Zitat Dienstag JL, Goldin RD, Heathcote EJ, et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105–117.CrossRefPubMed Dienstag JL, Goldin RD, Heathcote EJ, et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105–117.CrossRefPubMed
20.
Zurück zum Zitat Guan R, Lai CL, Leung NWY, et al.: Efficacy and safety of 5 years lamivudine treatment of Chinese pateints with chronic hepatitis B [abstract]. J Gastroenterol Hepatol 2001, 16:A60. Guan R, Lai CL, Leung NWY, et al.: Efficacy and safety of 5 years lamivudine treatment of Chinese pateints with chronic hepatitis B [abstract]. J Gastroenterol Hepatol 2001, 16:A60.
21.
Zurück zum Zitat Leung NW, Lai CL, Chang TT, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527–1532.CrossRefPubMed Leung NW, Lai CL, Chang TT, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527–1532.CrossRefPubMed
22.
Zurück zum Zitat Liaw YF, Leung NW, Chang TT, et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000, 119:172–180. Liaw YF, Leung NW, Chang TT, et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000, 119:172–180.
23.
Zurück zum Zitat Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29:889–896.CrossRefPubMed Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29:889–896.CrossRefPubMed
24.
Zurück zum Zitat Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714–1722.CrossRefPubMed Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714–1722.CrossRefPubMed
25.
Zurück zum Zitat Epivir-HBV [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007. Epivir-HBV [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
26.
Zurück zum Zitat Adani GL, Baccarani U, Risaliti A, et al.: Rhabdomyolysis due to lamivudine administration in a liver transplant recipient. Am J Transplant 2005, 5:634.CrossRefPubMed Adani GL, Baccarani U, Risaliti A, et al.: Rhabdomyolysis due to lamivudine administration in a liver transplant recipient. Am J Transplant 2005, 5:634.CrossRefPubMed
27.
Zurück zum Zitat Yahagi K, Ueno Y, Mano Y, et al.: Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 2002, 8:1198–1199.CrossRefPubMed Yahagi K, Ueno Y, Mano Y, et al.: Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 2002, 8:1198–1199.CrossRefPubMed
28.
Zurück zum Zitat Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009. Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
29.
Zurück zum Zitat Bayrakci US, Baskin E, Ozcay F, et al.: Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008, 12:109–112.CrossRefPubMed Bayrakci US, Baskin E, Ozcay F, et al.: Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008, 12:109–112.CrossRefPubMed
30.
Zurück zum Zitat Cupler EJ, Dalakas MC: Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995, 345:460–461.CrossRefPubMed Cupler EJ, Dalakas MC: Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995, 345:460–461.CrossRefPubMed
31.
Zurück zum Zitat Ojetti V, Gasbarrini A, Migneco A, et al.: Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis 2002, 34:384–385.CrossRefPubMed Ojetti V, Gasbarrini A, Migneco A, et al.: Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis 2002, 34:384–385.CrossRefPubMed
32.
Zurück zum Zitat Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670–1677.CrossRefPubMed Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670–1677.CrossRefPubMed
33.
Zurück zum Zitat Stuyver LJ, Locarnini SA, Lok A, et al.: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751–757.CrossRefPubMed Stuyver LJ, Locarnini SA, Lok A, et al.: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751–757.CrossRefPubMed
34.
Zurück zum Zitat Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.CrossRefPubMed Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.CrossRefPubMed
35.
Zurück zum Zitat Fung SK, Chae HB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44:283–290.CrossRefPubMed Fung SK, Chae HB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44:283–290.CrossRefPubMed
36.
Zurück zum Zitat •• Marcellin P, Chang TT, Lim SG, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750–758. This paper discusses the efficacy and safety of adefovir given beyond 1 year in HBeAg-positive chronic hepatitis B. CrossRefPubMed •• Marcellin P, Chang TT, Lim SG, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750–758. This paper discusses the efficacy and safety of adefovir given beyond 1 year in HBeAg-positive chronic hepatitis B. CrossRefPubMed
37.
Zurück zum Zitat Chang TT, Shiffman ML, Tong M, et al.: Durability of HBeAg seroconversion following adefovir diivoxil treatment for chronic hepatitis B [abstract]. J Hepatol 2006, 44:S187.CrossRef Chang TT, Shiffman ML, Tong M, et al.: Durability of HBeAg seroconversion following adefovir diivoxil treatment for chronic hepatitis B [abstract]. J Hepatol 2006, 44:S187.CrossRef
38.
Zurück zum Zitat Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.CrossRefPubMed Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.CrossRefPubMed
39.
Zurück zum Zitat Marcellin P, Jacobson I, Habersetzer F, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008, 48:S26.CrossRef Marcellin P, Jacobson I, Habersetzer F, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008, 48:S26.CrossRef
40.
Zurück zum Zitat Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673–2681.CrossRefPubMed Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673–2681.CrossRefPubMed
41.
Zurück zum Zitat Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.CrossRefPubMed Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.CrossRefPubMed
42.
Zurück zum Zitat Shiffman ML, Marcellin P, Jeffers L, et al.: HBsAg seroconversion in adefovir dipivoxil treated chronic hepatitis B patients [abstract]. J Hepatol 2004, 40:17.CrossRef Shiffman ML, Marcellin P, Jeffers L, et al.: HBsAg seroconversion in adefovir dipivoxil treated chronic hepatitis B patients [abstract]. J Hepatol 2004, 40:17.CrossRef
43.
Zurück zum Zitat Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673.CrossRefPubMed Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673.CrossRefPubMed
44.
Zurück zum Zitat Benhamou Y, Bochet M, Thibault V, et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001, 358:718–723.CrossRefPubMed Benhamou Y, Bochet M, Thibault V, et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001, 358:718–723.CrossRefPubMed
45.
Zurück zum Zitat Perrillo R, Hann HW, Mutimer D, et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126:81–90.CrossRefPubMed Perrillo R, Hann HW, Mutimer D, et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126:81–90.CrossRefPubMed
46.
Zurück zum Zitat Peters MG, Hann Hw H, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91–101.CrossRefPubMed Peters MG, Hann Hw H, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91–101.CrossRefPubMed
47.
Zurück zum Zitat Schiff E, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349–360.CrossRefPubMed Schiff E, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349–360.CrossRefPubMed
48.
Zurück zum Zitat Izzedine H, Hulot JS, Launay-Vacher V, et al.: Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66:1153–1158.CrossRefPubMed Izzedine H, Hulot JS, Launay-Vacher V, et al.: Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66:1153–1158.CrossRefPubMed
49.
Zurück zum Zitat Ha NB, Garcia RT, Trinh HN, et al.: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50:727–734.CrossRefPubMed Ha NB, Garcia RT, Trinh HN, et al.: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50:727–734.CrossRefPubMed
50.
Zurück zum Zitat Westland CE, Yang H, Delaney WEt, et al.: Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003, 38:96–103CrossRefPubMed Westland CE, Yang H, Delaney WEt, et al.: Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003, 38:96–103CrossRefPubMed
51.
Zurück zum Zitat Yang H, Westland CE, Delaney WE 4th, et al.: Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36:464–473.CrossRefPubMed Yang H, Westland CE, Delaney WE 4th, et al.: Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36:464–473.CrossRefPubMed
52.
Zurück zum Zitat Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292–297.CrossRefPubMed Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292–297.CrossRefPubMed
53.
Zurück zum Zitat Borroto-Esoda K, Miller MD, Arterburn S: Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007, 47:492–498.CrossRefPubMed Borroto-Esoda K, Miller MD, Arterburn S: Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007, 47:492–498.CrossRefPubMed
54.
Zurück zum Zitat Villeneuve JP, Durantel D, Durantel S, et al.: Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003, 39:1085–1089.CrossRefPubMed Villeneuve JP, Durantel D, Durantel S, et al.: Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003, 39:1085–1089.CrossRefPubMed
55.
56.
Zurück zum Zitat Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001–1010.CrossRefPubMed Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001–1010.CrossRefPubMed
57.
Zurück zum Zitat Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437–1444.CrossRefPubMed Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437–1444.CrossRefPubMed
58.
Zurück zum Zitat •• Han SH, Chang TT, Chao YC, et al.: Five years of continuous entecavir for nucleoside-naive HBeAg(+) chornic hepatitis B: results from studies ETV-022/-901 [abstract]. Hepatology 2008, 48:705A. This abstract reports the efficacy and safety of entecavir therapy for 5 years in HBeAg-positive chronic hepatitis B. •• Han SH, Chang TT, Chao YC, et al.: Five years of continuous entecavir for nucleoside-naive HBeAg(+) chornic hepatitis B: results from studies ETV-022/-901 [abstract]. Hepatology 2008, 48:705A. This abstract reports the efficacy and safety of entecavir therapy for 5 years in HBeAg-positive chronic hepatitis B.
59.
Zurück zum Zitat Leung N, Peng CY, Hann HW, et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72–79.CrossRefPubMed Leung N, Peng CY, Hann HW, et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72–79.CrossRefPubMed
60.
Zurück zum Zitat Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.CrossRefPubMed Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.CrossRefPubMed
61.
Zurück zum Zitat •• Shouval D, Lai CL, Chang TT, et al.: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50:289–295. This paper discusses the relapse risk in HBeAg-negative patients who received entecavir treatment. CrossRefPubMed •• Shouval D, Lai CL, Chang TT, et al.: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50:289–295. This paper discusses the relapse risk in HBeAg-negative patients who received entecavir treatment. CrossRefPubMed
62.
Zurück zum Zitat •• Shouval D, Lai CL, Chang TT, et al.: Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901 [abstract]. Hepatology 2008, 48. This paper reports the results of retreatment with entecavir in HBeAg-negative patients who relapsed following discontinuation of initial entecavir therapy. •• Shouval D, Lai CL, Chang TT, et al.: Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901 [abstract]. Hepatology 2008, 48. This paper reports the results of retreatment with entecavir in HBeAg-negative patients who relapsed following discontinuation of initial entecavir therapy.
63.
Zurück zum Zitat Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198–1209.CrossRefPubMed Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198–1209.CrossRefPubMed
64.
Zurück zum Zitat Colonno R, Rose RE, Pokornowski K, et al.: Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007, 46:S294.CrossRef Colonno R, Rose RE, Pokornowski K, et al.: Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007, 46:S294.CrossRef
65.
Zurück zum Zitat •• Tenney D, Pokornowski K, Rose RE, et al.: Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. Gastroenterology 2009, 135:A865. This abstract provides the longest follow-up data on the risk of virologic resistance of entecavir after 6 years of therapy in nucleoside-naïve patients. •• Tenney D, Pokornowski K, Rose RE, et al.: Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. Gastroenterology 2009, 135:A865. This abstract provides the longest follow-up data on the risk of virologic resistance of entecavir after 6 years of therapy in nucleoside-naïve patients.
66.
Zurück zum Zitat • Tsai N, Min A, Manns M, et al.: Low rates of nucleos(t)ide associated adverse events in the long-term experience with entecavir [abstract]. Gastroenterology 2010:M1901. This abstract reviews the adverse events associated with long-term therapy with entecair using pooled data from several studies. • Tsai N, Min A, Manns M, et al.: Low rates of nucleos(t)ide associated adverse events in the long-term experience with entecavir [abstract]. Gastroenterology 2010:M1901. This abstract reviews the adverse events associated with long-term therapy with entecair using pooled data from several studies.
67.
Zurück zum Zitat •• Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006. This recent report series highlights the risk of severe lactic acidosis with entecavir therapy in patients with more advanced liver disease. CrossRefPubMed •• Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006. This recent report series highlights the risk of severe lactic acidosis with entecavir therapy in patients with more advanced liver disease. CrossRefPubMed
68.
Zurück zum Zitat Tenney DJ, Rose RE, Baldick CJ, et al.: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503–1514.CrossRefPubMed Tenney DJ, Rose RE, Baldick CJ, et al.: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503–1514.CrossRefPubMed
69.
Zurück zum Zitat Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498–3507.CrossRefPubMed Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498–3507.CrossRefPubMed
70.
Zurück zum Zitat Lai CL, Gane E, Liaw YF, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576–2588.CrossRefPubMed Lai CL, Gane E, Liaw YF, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576–2588.CrossRefPubMed
71.
Zurück zum Zitat •• Liaw YF, Gane E, Leung N, et al.: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486–495. This follow-up article reports on the 2-year efficacy and safety data of telbivudine registration trial. CrossRefPubMed •• Liaw YF, Gane E, Leung N, et al.: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486–495. This follow-up article reports on the 2-year efficacy and safety data of telbivudine registration trial. CrossRefPubMed
72.
Zurück zum Zitat • Jia JD, Hou JL, Yin YK, et al.: Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J Hepatol 2007, 46:S189. This article reports on the 2-year efficacy and safety data of telbivudine in Chinese patients. CrossRef • Jia JD, Hou JL, Yin YK, et al.: Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J Hepatol 2007, 46:S189. This article reports on the 2-year efficacy and safety data of telbivudine in Chinese patients. CrossRef
73.
Zurück zum Zitat Chan HL, Heathcote EJ, Marcellin P, et al.: Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745–754.PubMed Chan HL, Heathcote EJ, Marcellin P, et al.: Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745–754.PubMed
74.
Zurück zum Zitat •• Fleischer RD, Lok AS: Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009, 51:787–791. This is a review article on the risk of myopathy and neuropathy associated with oral anti-hepatitis B therapy. CrossRefPubMed •• Fleischer RD, Lok AS: Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009, 51:787–791. This is a review article on the risk of myopathy and neuropathy associated with oral anti-hepatitis B therapy. CrossRefPubMed
75.
Zurück zum Zitat Goncalves J, Laeufle R, Avila C: Increased risk with combination of telbivudine and pegylated-interferon alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database. J Hepatol 2009, 50:S329.CrossRef Goncalves J, Laeufle R, Avila C: Increased risk with combination of telbivudine and pegylated-interferon alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database. J Hepatol 2009, 50:S329.CrossRef
76.
Zurück zum Zitat Gane E, Lai CL, Min A, et al.: Adefovir salvage therpay for virologic breakthrough in telbivudine-treated patients from the GLOBE study [abstract]. J Hepatol 2007, 46:S187. Gane E, Lai CL, Min A, et al.: Adefovir salvage therpay for virologic breakthrough in telbivudine-treated patients from the GLOBE study [abstract]. J Hepatol 2007, 46:S187.
77.
Zurück zum Zitat Heathcote EJ, George J, Gordon S, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103) [abstract]. J Hepatol 2008, 48:S32.CrossRef Heathcote EJ, George J, Gordon S, et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103) [abstract]. J Hepatol 2008, 48:S32.CrossRef
78.
Zurück zum Zitat Heathcote EJ, Gane E, De Man R, et al.: Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103), preliminary analysis [abstract]. Hepatology 2009, 50:533A. Heathcote EJ, Gane E, De Man R, et al.: Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103), preliminary analysis [abstract]. Hepatology 2009, 50:533A.
79.
Zurück zum Zitat Marcellin P, Buti M, Krastev Z, et al.: Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102); preliminary analysis [abstract]. Hepatology 2009, 50:532A. Marcellin P, Buti M, Krastev Z, et al.: Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102); preliminary analysis [abstract]. Hepatology 2009, 50:532A.
80.
Zurück zum Zitat Snow-Lampart A, Chappel BJ, Curtis M, et al.: Resistance surveillance for up to 144 weeks in HBeAg + and HBeAg- hepatitis B patients treated wtih tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase [abstract]. Hepatology 2009, 50:532A. Snow-Lampart A, Chappel BJ, Curtis M, et al.: Resistance surveillance for up to 144 weeks in HBeAg + and HBeAg- hepatitis B patients treated wtih tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase [abstract]. Hepatology 2009, 50:532A.
Metadaten
Titel
Antiviral Therapy: Analysis of Long-term Efficacy and Safety
verfasst von
Helen S. Te
Publikationsdatum
01.11.2010
Verlag
Current Science Inc.
Erschienen in
Current Hepatology Reports / Ausgabe 4/2010
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-010-0052-4

Weitere Artikel der Ausgabe 4/2010

Current Hepatology Reports 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.